New drug SON-DP enters early human trials for liver and stomach cancers
NCT ID NCT06873659
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new drug called SON-DP in 96 adults with advanced solid tumors, specifically liver and gastric cancers. The main goals are to check the drug's safety, find the right dose, and see if it can control the disease. Participants receive SON-DP through an IV, and researchers will monitor side effects, tumor response, and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SON-DP (a drug given through an IV)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver or gastric cancers.
What could go wrong
This is a very early Phase 1 trial with only 96 people, so it is primarily checking safety and dosing. The drug may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102200, China
Contact
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
-
Introduction to Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)
RECRUITINGJinan, Shandong, 250117, China
Contact
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Contact
Contact
-
The First Affiliated Hospital of Xi 'an Jiaotong University
RECRUITINGXi'an, Shaanxi, 710061, China
Contact
-
The First Hospital of Lanzhou University
RECRUITINGLanzhou, Gansu, 730000, China
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
-
ZhongShan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact